drugset / Trial / NCT01680900
Vilazodone for Menopausal Hot Flashes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a pilot study to determine proof in principle that vilazodone, a selective serotonin reuptake inhibitor and 5HT1a agonist, reduces the frequency and severity of menopausal hot flashes relative to placebo. A secondary aim is to evaluate improvement in menopause-related quality of life.
Timeline
- Start
- 2012-11
- Primary completion
- 2013-08
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vilazodone | Small molecule | 20 mg | — |
| Subject | Vilazodone | Small molecule | 40 mg | — |
Indications
No indication recorded.